Brief: Immunoprecise Validates Lensai Epitope Mapping Platform Across Broad Range Of Unseen Therapeutic Targets Beyond Training Data
03/07/2025 13:20
Immunoprecise Antibodies Ltd IPA.O: IMMUNOPRECISE VALIDATES LENSAI EPITOPE MAPPING PLATFORM ACROSS BROAD RANGE OF UNSEEN THERAPEUTIC TARGETS BEYOND TRAINING DATA Source text: ID:nBw7X3zZ7a Further company coverage: IPA.O
Recent news on Mindwalk Holdings
See all newsBrief: Mindwalk Holdings Corp. Announces Leadership Update
MindWalk Holdings Corp reports results for the quarter ended July 31 - Earnings Summary
Canada's MindWalk Q1 net loss widens on higher sales, marketing expenses
MindWalk Holdings Corp expected to post a loss of 8 cents a share - Earnings Preview
Brief: MindWalk Showcases Reefiq™ For Ai Drug Discovery At AMD Advancing Ai